Dr. Chen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 206-288-1000Fax+1 608-263-9830
Education & Training
University of WashingtonFellowship, Hematopathology, 2011 - 2012
University of Wisconsin Hospitals and ClinicsResidency, Pathology-Anatomic and Clinical, 2007 - 2011
Beijing Medical UniversityClass of 1995
Certifications & Licensure
WA State Medical License 2011 - 2025
WI State Medical License 2008 - 2011- American Board of Pathology Pathology - Anatomic/Pathology - Clinical
- American Board of Pathology Hematopathology
Publications & Presentations
PubMed
- Acute Myeloid Leukemia: Diagnosis and Evaluation by Flow Cytometry.Feras Ally, Xueyan Chen
Cancers. 2024-11-17 - Utility of CCR7 to differentiate classic Hodgkin lymphoma and other B-cell lymphomas by flow cytometry and immunohistochemistry.Xueyan Chen, Lori Soma, Claire Murphy, Maria Tretiakova, Kikkeri N Naresh
American Journal of Clinical Pathology. 2024-09-16 - Clinicopathologic features and outcomes of acute leukemia harboring PICALM::MLLT10 fusion.Jeffrey Wang, Weiwei Zhang, Xinjie Xu, Alessia Buglioni, Peng Li
Human Pathology. 2024-09-01
Abstracts/Posters
- Comprehensive Evaluation and Validation of a Next-Generation Sequencing Assay for Minimal Residual Disease Detection in T-Lymphoblastic Leukemia/LymphomaXueyan Chen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast Count61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
A 36-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial of Sodium Oligomannate for Mild-to-Moderate Alzheimer’s DementiaMarch 17th, 2021
Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort StudyMarch 15th, 2016
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
